{"entity":{"id":"sti-6129","kind":"drug","name":"STI-6129","aka":[],"tldr":"STI-6129 is an experimental antibody-drug conjugate from Zhejiang ACEA Pharmaceutical in phase 2 trials for multiple myeloma, aimed at CD38.","summary":"STI-6129 is an antibody-drug conjugate developed by Zhejiang ACEA Pharmaceutical. Its target is CD38 (the sponsor names CD38). The sponsor states: Anti-CD38 human antibody covalently bound to a duostatin tubulin inhibitor payload. ClinicalTrials.gov describes the intervention as: Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT05565807, plans to enrol 84 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of STI-6129","url":"https://clinicaltrials.gov/search?intr=STI-6129"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":["cd38"],"drugs":[],"companies":["sorrento-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05565807"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"Anti-CD38 human antibody covalently bound to a duostatin tubulin inhibitor payload.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sti-6129/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"target":[{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"}],"company":[{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/"}],"trial":[{"id":"nct05565807","kind":"trial","name":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05565807/"}]}}